We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01902160
Recruitment Status : Completed
First Posted : July 18, 2013
Last Update Posted : November 9, 2015
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : May 2015
  Study Completion Date : No date given